The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients.
Platelet-activating factor (PAF) is transformed in vivo rapidly into the biologically inactive lyso-PAF. This reaction as well as lipid parameters were quantified in serum from 40 survivors of myocardial infarction and 36 healthy controls matched for age and body weight. The PAF-degrading capacity was 23% (p less than 0.001) higher in patients compared with the control group. Using the degradation of PAF as an univariate discriminator more than 70% of subjects were classified correctly. This is comparable with the discriminatory value of the best lipid variables, apolipoprotein B and HDL-cholesterol. Statistically significant differences in the degradation of PAF were found also by comparing subgroups which were matched for plasma levels of total cholesterol, VLDL/LDL-cholesterol or apolipoprotein B. The ratio by 48% (p less than 0.0001) in the case group was identified as an additional good discriminator between both groups. In contrast, platelet aggregation tests which were performed in acetylsalicyclic acid treated platelet-rich plasma discriminated poorly between patients and controls.
Ostermann
G
G
Institut für Pathologische Biochemie, Medizinische Akademie, Erfurt, DDR.
Lang
A
A
Holtz
H
H
Rühling
K
K
Winkler
L
L
Till
U
U
D001053:Apolipoproteins / Q000097:blood; D001161:Arteriosclerosis / Q000097:blood*; D015415:Biomarkers / Q000097:blood*; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D009203:Myocardial Infarction / Q000097:blood; D010972:Platelet Activating Factor / Q000378:metabolism*; D010979:Platelet Function Tests; D011237:Predictive Value of Tests
D001053:Apolipoproteins; D015415:Biomarkers; D008055:Lipids; D010972:Platelet Activating Factor